Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › THYROCARE

THYROCARE

Thyrocare Technologies Limited
Micro-capPharma ↗

What the six lenses say about THYROCARE — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹573.1
2026-09-08
VWAP · 1Y anchor
₹473
+21.2% from VWAP
P/E · TTM
55.9×
TTM EPS ₹10.3
52-week range
75%
position low→high
RSI(14)
46
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How THYROCARE’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
7.5
avg conviction decile
Leadership
—
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Micro-cap cohortDRaw
TechnicalD788›

The actual numbers

Price vs VWAP (1y)+21.2%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+17.8%
Price vs 50-EMA+0.7%
RSI(14)46
RS vs Nifty 500 · 3M+1.4%
RS vs sector · 3M-4.6%
52-week range75%
Volume vs 30d avg0.25×
Volume vs 60d avg0.20×
ATR(14) · volatility24.9
Bollinger width · vol contraction0.162
FundamentalD1072›

The actual numbers

Return on equity (ROE)27.9%
Operating margin26.0%
Net margin19.6%
Revenue growth · YoY+20.8%
EPS growth · YoY-29.1%
Debt / equity0.09×

Full 8-quarter history in the financials table below.

ValuationD29›

The actual numbers

P/E (TTM)55.9×
TTM EPS₹10.3
52-week range75%
CatalystD849›

The actual numbers

Earnings & momentum30
Capital actions60
Governance97

Every filing in the corporate-announcements panel below.

FlowD860›

The actual numbers

Promoter holding60.9%
Delivery · 30d avg52.5%
Up/down-day asymmetry1.8pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Micro-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D7 + D8 ) ÷ 2 = 7.5(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
85
Conviction score 85/100 · avg-decile strength 7.5/10
Conviction score85/100›
TechnicalD7›
FundamentalD10›
ValuationD2›
CatalystD8›
FlowD8›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
-0.0pp
-3.9pp
-0.7pp
+3.0pp
+57.7pp
+34.1pp
Nifty 500
Broad-market baseline
-0.1pp
-3.9pp
-1.7pp
+1.4pp
+52.0pp
+28.9pp
Sector
Own-sector index
—
—
-4.6pp
-4.6pp
+38.8pp
+8.1pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

THYROCARE daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
573.15-3.00

Relative strength

RS vs baseline · rebased to 100

THYROCARE ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
203.75-0.20

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)157177166187193217196224
↳ change QoQ—+13.0%-6.4%+12.7%+3.2%+12.4%-9.7%+14.3%
EBITDA (₹cr)4651465758715875
EBITDA margin29.5%28.7%27.6%30.5%30.0%32.7%29.6%33.5%
PAT (₹cr)2447192238482849
↳ change QoQ—+96.9%-59.8%+16.1%+72.7%+26.3%-41.7%+75.0%
Net margin15.3%26.6%11.4%11.8%19.7%22.1%14.3%21.9%
EPS (₹)4.524.993.581.362.453.021.822.96
D/E————————
YoY growth · Mar '26Revenue +19.8% YoYPAT +122.7% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 4 Sep '26
    MEDIUMgovernance
    Disclosure under SEBI Takeover Regulations
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 1 Sep '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 19 Aug '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 18 Aug '26
    MEDIUMgovernance
    Disclosure under SEBI Takeover Regulations
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 18 Aug '26
    MEDIUMgovernance
    Disclosure under SEBI Takeover Regulations
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 17 Aug '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 13 Aug '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 13 Aug '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 27 Jul '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 24 Jul '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 23 Jul '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 23 Jul '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 23 Jul '26
    MEDIUMgovernance
    Appointment
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 23 Jul '26
    MEDIUMearnings
    Investor Presentation
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 23 Jul '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds THYROCARE

Mutual funds holding THYROCARE (10)

FundWeightAUM ₹crGrade
HSBC Midcap Gr1.63%15,578
Aditya BSL ELSS Tax Saver Gr LSP1.32%14,660
Aditya BSL ELSS Tax Saver Gr1.32%14,660
Nippon India Pharma Bns2.51%9,279
Nippon India Pharma Gr2.51%9,279
ICICI Pru Pharma Healthcare Diag Gr1.95%6,803
HSBC Large & Mid Cap Reg Gr1.84%5,479
HDFC Pharma and Healthcare Reg Gr1.42%2,940
Bank of India Small Cap Reg Gr0.82%2,819
Aditya BSL Pharma & Hlthcare Reg Gr1.91%1,074

ETFs holding THYROCARE (0)

No tracked ETF holds THYROCARE ≥0.5%.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma